Candriam S.C.A. Natera, Inc. Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in Natera, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 306,615 shares of NTRA stock, worth $46.3 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares

306,615

Previous 200,007 53.3%

Holding current value

$46.3 Million

Previous $21.7 Million 79.93%

% of portfolio

0.23%

Previous 0.13%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$97.75 - $129.67 $10.4 Million - $13.8 Million	106,608 Added 53.3%	306,615 $39 Million
Q2 2024 Aug 05, 2024	SELL	$85.28 - $112.6 $2.39 Million - $3.15 Million	-28,001 Reduced 12.28%	200,007 $21.7 Million
Q1 2024 May 03, 2024	SELL	$59.21 - $92.9 $827,696 - $1.3 Million	-13,979 Reduced 5.78%	228,008 $20.9 Million
Q4 2023 Feb 14, 2024	SELL	$37.55 - $62.64 $1.8 Million - $3.01 Million	-48,003 Reduced 16.55%	241,987 $15.2 Million
Q3 2023 Nov 13, 2023	SELL	$43.4 - $62.52 $652,041 - $939,300	-15,024 Reduced 4.93%	289,990 $12.8 Million
Q2 2023 Aug 08, 2023	BUY	$47.08 - $55.16 $8.51 Million - $9.98 Million	180,851 Added 145.66%	305,014 $14.8 Million
Q1 2023 May 12, 2023	BUY	$36.57 - $58.29 $2.53 Million - $4.03 Million	69,163 Added 125.75%	124,163 $6.89 Million
Q4 2022 Feb 13, 2023	BUY	$34.17 - $47.91 $341,700 - $479,099	10,000 Added 22.22%	55,000 $2.21 Million
Q3 2022 Nov 10, 2022	BUY	$36.93 - $56.68 $1.66 Million - $2.55 Million	45,000 New	45,000 $1.97 Million
Q1 2022 May 13, 2022	SELL	$30.32 - $91.33 $290,223 - $874,210	-9,572 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$86.26 - $119.0 $65,298 - $90,083	757 Added 8.59%	9,572 $894,000
Q3 2021 Nov 09, 2021	BUY	$100.17 - $126.36 $882,998 - $1.11 Million	8,815 New	8,815 $982,000

Others Institutions Holding NTRA

# of Institutions

522

Shares Held

119M

Call Options Held

298K

Put Options Held

185K

View Full List

About Natera, Inc.

Ticker NTRA
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 96,957,400
Market Cap $14.7B
Description
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...

More about NTRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account